You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic hormone-sensitive prostate cancer (mHSPC)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Learn More About How Safe Darolutamide is Under Real-world

Not yet recruiting
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • No Intervention
  • Multiple Locations, Japan
    Many Locations
Aug 24, 2023

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) Trial (dalpiciclib isethionate tablets; abiraterone acetate

Not yet recruiting
  • High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
  • dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
  • placebo; abiraterone acetate tablets; prednisone tablets
  • (no location specified)
Oct 20, 2023

Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)

Recruiting
  • Metastatic Prostate Cancer
  • +2 more
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of

Recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • 6-month course of antiandrogen drugs
  • Long-term course of antiandrogen drugs
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023

Apalutamide in Metastatic Hormone Sensitive Prostate Cancer

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    • Cardiff, United Kingdom
    • +4 more
    Aug 25, 2023

    Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide

    Not yet recruiting
    • Prostate Adenocarcinoma
    • +2 more
    • Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
    • Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
    • Boston, Massachusetts
      Beth Israel Deaconess Medical Center
    Jan 4, 2023

    Metastatic Hormone Sensitive Prostate Cancer Trial in China (Enzalutamide, Placebo, Androgen deprivation therapy (ADT))

    Active, not recruiting
    • Metastatic Hormone Sensitive Prostate Cancer
    • Beijing, China
    • +29 more
    Jan 7, 2023

    Prostate Cancer Metastatic Trial in New York (REGN2810, Degarelix, Leuprolide Acetate)

    Recruiting
    • Prostate Cancer Metastatic
    • New York, New York
      Columbia University Irving Medical Center
    Mar 22, 2022

    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial (Standard ADT (androgen deprivation therapy), Standard Darolutamide,

    Not yet recruiting
    • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    • Standard ADT (androgen deprivation therapy)
    • +2 more
    • (no location specified)
    Jan 6, 2023

    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Milano, Milan (APA + ADT, Local Treatmetn RT or RP)

    Not yet recruiting
    • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    • APA + ADT
    • Local Treatmetn RT or RP
    • Milano, Lombardia, Italy
    • +2 more
    Jan 17, 2023

    Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 Trial (Pharmacotherapy

    Not yet recruiting
    • Castration-Sensitive Prostate Carcinoma
    • +4 more
    • Pharmacotherapy Discontinuation
    • +3 more
    • (no location specified)
    Feb 11, 2022

    Metastatic Hormone Sensitive Prostate Cancer Treated With

    Not yet recruiting
    • Metastatic Hormone-sensitive Prostate Cancer
    • Innsbruck, Austria
    • +42 more
    Jun 5, 2023

    Metastatic Hormone-Sensitive Prostate Cancer Trial in China (biological, drug, procedure, other)

    Active, not recruiting
    • Metastatic Hormone-Sensitive Prostate Cancer
    • Pembrolizumab
    • +3 more
    • Beijing, Beijing, China
    • +23 more
    Sep 30, 2022

    Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer Trial in Shanghai (drug, procedure, radiation)

    Not yet recruiting
    • Metastatic Prostate Cancer
    • Castration-Sensitive Prostate Cancer
    • Shanghai, Shanghai, China
    • +1 more
    Feb 4, 2023

    Metastatic Prostate Cancer Trial in Guangzhou (Metformin)

    Not yet recruiting
    • Metastatic Prostate Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 8, 2021

    Metastatic Hormone-sensitive Prostate Cancer Trial in United States (Darolutamide (BAY1841788, Nubeqa), ADT)

    Recruiting
    • Metastatic Hormone-sensitive Prostate Cancer
    • Darolutamide (BAY1841788, Nubeqa)
    • ADT
    • Homewood, Alabama
    • +11 more
    Jan 13, 2023

    Metastatic Hormone-Sensitive Prostate Cancer Trial (Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment)

    Not yet recruiting
    • Metastatic Hormone-Sensitive Prostate Cancer
    • (no location specified)
    Nov 10, 2023

    Based Discrete Choice Experiment Study in Prostate Cancer Study

    Completed
    • Prostate Cancer
    • Metastatic Hormone-sensitive Prostate Cancer
      • Durham, North Carolina
        Duke Clinical Research Institute
      Jan 10, 2023

      Oligometastatic Hormone Sensitive Prostate Cancer Trial in Florence (SBRT on all sites of metastatic disease+Apalutamide)

      Not yet recruiting
      • Oligometastatic Hormone Sensitive Prostate Cancer
      • SBRT on all sites of metastatic disease+Apalutamide
      • Florence, Italy
        AOU Careggi Radiation Oncology Unit
      Jan 29, 2023

      Prostate Cancer Trial in Chicago (Docetaxel, ADT, Abiraterone)

      Not yet recruiting
      • Prostate Cancer
      • Chicago, Illinois
        Northwestern University
      Sep 27, 2023

      Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer Trial in Umeå (Moderate hypo-fractionation,

      Recruiting
      • Prostate Cancer
      • +2 more
      • Moderate hypo-fractionation
      • Ultra-hypo-fractionation
      • Umeå, Sweden
        Cancercenter University hospital of Umeå
      Nov 1, 2022

      Learn About Novel Hormonal Therapies in People With Metastatic

      Not yet recruiting
      • Prostatic Neoplasms
      • Novel hormonal therapy
      • New York, New York
        Pfizer Inc
      Oct 2, 2023

      Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency, Chemo Effect Trial in Nanjing (Docetaxel,

      Recruiting
      • Hormone Sensitive Metastatic Prostate Cancer
      • +3 more
      • Nanjing, Jiangsu, China
        Department of Urology, Drum Tower Hospital, Medical School of Na
      Jul 13, 2022

      Metastatic Hormone Refractory Prostate Cancer Trial in Saint Louis (Cabozantinib, Nivolumab, Abiraterone acetate)

      Recruiting
      • Metastatic Hormone Refractory Prostate Cancer
      • Saint Louis, Missouri
        Washington University School of Medicine
      Jun 6, 2022

      Metastatic Hormone Sensitive Prostate Cancer Trial in Worldwide (Enzalutamide, Placebo)

      Active, not recruiting
      Has Results
      • Metastatic Hormone Sensitive Prostate Cancer
      • Homewood, Alabama
      • +202 more
      Jul 29, 2022